A citation-based method for searching scientific literature

M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
Brian T Burgess, Abigail M Anderson, J Robert McCorkle, Jianrong Wu, Frederick R Ueland, Jill M Kolesar. Diagnostics (Basel) 2020
15
50

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Claire Fritz, Scott M Portwood, Amanda Przespolewski, Eunice S Wang. Blood Rev 2021
4
50

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Tatiana Kamaletdinova, Zahra Fanaei-Kahrani, Zhao-Qi Wang. Cells 2019
26
50

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Britta Stordal, Kirsten Timms, Angela Farrelly, Danielle Gallagher, Steven Busschots, Mickaël Renaud, Julien Thery, Deborah Williams, Jennifer Potter, Thanh Tran,[...]. Mol Oncol 2013
87
50

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
846
50

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Bhavana Pothuri, Roisin O'Cearbhaill, Ramez Eskander, Deborah Armstrong. Gynecol Oncol 2020
4
50

Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3.
Carole Beck, Isabelle Robert, Bernardo Reina-San-Martin, Valérie Schreiber, Françoise Dantzer. Exp Cell Res 2014
165
50

PARP inhibitors in gastric cancer: beacon of hope.
Yali Wang, Kun Zheng, Yongbiao Huang, Hua Xiong, Jinfang Su, Rui Chen, Yanmei Zou. J Exp Clin Cancer Res 2021
1
100



Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
Christiana DelloRusso, Piri L Welcsh, Weixin Wang, Rochelle L Garcia, Mary-Claire King, Elizabeth M Swisher. Mol Cancer Res 2007
83
50


PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
Jaydira del Rivero, Elise C Kohn. Oncology (Williston Park) 2017
23
50

Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Dariush Etemadmoghadam, Barbara A Weir, George Au-Yeung, Kathryn Alsop, Gillian Mitchell, Joshy George, Sally Davis, Alan D D'Andrea, Kaylene Simpson, William C Hahn,[...]. Proc Natl Acad Sci U S A 2013
125
50

C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
Jiahong Tan, Xu Zheng, Mengchen Li, Fei Ye, Chunyan Song, Cheng Xu, Xiaoxue Zhang, Wenqian Li, Ya Wang, Shaoqing Zeng,[...]. Oncogene 2021
1
100


Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
963
50

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Giorgio Valabrega, Giulia Scotto, Valentina Tuninetti, Arianna Pani, Francesco Scaglione. Int J Mol Sci 2021
1
100

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Sarah J Hill, Brennan Decker, Emma A Roberts, Neil S Horowitz, Michael G Muto, Michael J Worley, Colleen M Feltmate, Marisa R Nucci, Elizabeth M Swisher, Huy Nguyen,[...]. Cancer Discov 2018
118
50


The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival.
T Jubin, A Kadam, M Jariwala, S Bhatt, S Sutariya, A R Gani, S Gautam, R Begum. Cell Prolif 2016
45
50

Erratum to 'Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis' [Eur J Cancer 149 (2021) 134-152].
Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido,[...]. Eur J Cancer 2021
1
100

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley,[...]. Nat Commun 2021
5
50


Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.
Michael S Anglesio, Kimberly C Wiegand, Nataliya Melnyk, Christine Chow, Clara Salamanca, Leah M Prentice, Janine Senz, Winnie Yang, Monique A Spillman, Dawn R Cochrane,[...]. PLoS One 2013
10
50

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Todd A Hopkins, Yan Shi, Luis E Rodriguez, Larry R Solomon, Cherrie K Donawho, Enrico L DiGiammarino, Sanjay C Panchal, Julie L Wilsbacher, Wenqing Gao, Amanda M Olson,[...]. Mol Cancer Res 2015
127
50

Measuring Survival of Adherent Cells with the Colony-Forming Assay.
Lisa C Crowley, Melinda E Christensen, Nigel J Waterhouse. Cold Spring Harb Protoc 2016
38
50

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
728
50

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.
Patrick G Pilié, Carl M Gay, Lauren A Byers, Mark J O'Connor, Timothy A Yap. Clin Cancer Res 2019
92
50

Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Dariush Etemadmoghadam, Joshy George, Prue A Cowin, Carleen Cullinane, Maya Kansara, Kylie L Gorringe, Gordon K Smyth, David D L Bowtell. PLoS One 2010
73
50

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido,[...]. Eur J Cancer 2021
8
50

Type-specific cell line models for type-specific ovarian cancer research.
Michael S Anglesio, Kimberly C Wiegand, Nataliya Melnyk, Christine Chow, Clara Salamanca, Leah M Prentice, Janine Senz, Winnie Yang, Monique A Spillman, Dawn R Cochrane,[...]. PLoS One 2013
157
50

Clonogenic assay of cells in vitro.
Nicolaas A P Franken, Hans M Rodermond, Jan Stap, Jaap Haveman, Chris van Bree. Nat Protoc 2006
50

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
1
100

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
Lucy Gentles, Bojidar Goranov, Elizabeth Matheson, Ashleigh Herriott, Angelika Kaufmann, Sally Hall, Asima Mukhopadhyay, Yvette Drew, Nicola J Curtin, Rachel L O'Donnell. Cancers (Basel) 2019
8
50

PARP inhibitors in ovarian cancer.
J A Ledermann. Ann Oncol 2016
73
50

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
550
50


Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.
Nidhi Goel, McKenzie E Foxall, Carly Bess Scalise, Jaclyn A Wall, Rebecca C Arend. Mol Cancer Ther 2021
1
100

Characterization and properties of nine human ovarian adenocarcinoma cell lines.
S P Langdon, S S Lawrie, F G Hay, M M Hawkes, A McDonald, I P Hayward, D J Schol, J Hilgers, R C Leonard, J F Smyth. Cancer Res 1988
192
50


Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.
Monique D Topp, Lynne Hartley, Michele Cook, Valerie Heong, Emma Boehm, Lauren McShane, Jan Pyman, Orla McNally, Sumitra Ananda, Marisol Harrell,[...]. Mol Oncol 2014
81
50

The PARP superfamily.
Jean-Christophe Amé, Catherine Spenlehauer, Gilbert de Murcia. Bioessays 2004
50

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander,[...]. Lancet Oncol 2021
15
50

The role of PARP inhibitors in BRCA mutated pancreatic cancer.
Jeffrey Chi, Su Yun Chung, Ruwan Parakrama, Fatima Fayyaz, Jyothi Jose, Muhammad Wasif Saif. Therap Adv Gastroenterol 2021
2
50


Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Wataru Sakai, Elizabeth M Swisher, Céline Jacquemont, Kurapaty Venkatapoorna Chandramohan, Fergus J Couch, Simon P Langdon, Kaitlyn Wurz, Jake Higgins, Emily Villegas, Toshiyasu Taniguchi. Cancer Res 2009
195
50

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma,[...]. Nat Commun 2020
23
50

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo,[...]. Gynecol Oncol 2020
18
50

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
Karolina N Dziadkowiec, Emilia Gąsiorowska, Ewa Nowak-Markwitz, Anna Jankowska. Prz Menopauzalny 2016
66
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.